ACADIA PHARMACEUTICALS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
ACADIA PHARMACEUTICALS INC. (ACAD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 4.24 million shares for the 12-month period ending 2015-12-31, per its 10-K filed 2016-02-29.
Discontinued › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2016-02-29
- ACADIA PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2015 was 4.24M shares, a 68.37% increase from fiscal 2014.
- ACADIA PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2014 was 2.52M shares, a 28.91% increase from fiscal 2013.
- ACADIA PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2013 was 1.95M shares, a 18.36% increase from fiscal 2012.
- ACADIA PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2012 was 1.65M shares, a 2.26% increase from fiscal 2011.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month |
|---|---|
| 2015-12-31 | 4.24M shares 10-K · filed 2016-02-29 |
| 2014-12-31 | 2.52M shares 10-K · filed 2015-02-26 |
| 2013-12-31 | 1.95M shares 10-K · filed 2014-02-27 |
| 2012-12-31 | 1.65M shares 10-K · filed 2013-03-12 |
| 2011-12-31 | 1.61M shares 10-K · filed 2013-03-12 |
| 2010-12-31 | 1.76M shares 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |